Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism
Само за регистроване кориснике
2011
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The Human Genome and the Hap Map Projects as well as the extensive use of deep resequencing worldwide, have contributed to a massive catalogue of reported single nucleotide polymorphisms (SNPs) and other genetic variations in the human genome. Pharmacogenomics is an emerging field that combines genetics with pharmacokinetics and pharmacodynamics of the drug in attempt to understand inter-individual differences among patients and develop more accurate drug dosing. However, only for the minority of those variations an association with phenotype has been established. Here, we provide an overview of genes and genetic variants that influence inter-individual dosing of three of the most widely used drugs, namely warfarin, irinotecan and thiopurine drugs, to highlight a tangible benefit of translating genomic knowledge into clinical practice. Therefore, particular SNPs in vitamin K epoxide reductase complex subunit 1 (VKORC1), cytochrome P450 2C9 (CYP2C9), uridine diphosphate glucoronosyltran...sferase 1A1 (UGT1A1) and thiopurine S-methyltransferase (TPMT) genes has proven to be applicable for optimising the dosage in pursuit of maximum efficacy and minimum adverse effects. Thus, they set an important paradigm of implementation of pharmacogenomics in the mainstream clinical practice.
Кључне речи:
warfarin / thiopurine drugs / single nucleotide polymorphism / pharmacogenomics / irinotecan / Drug -metabolizing enzymesИзвор:
Current Drug Metabolism, 2011, 12, 5, 445-454Издавач:
- Bentham Science Publ Ltd, Sharjah
Финансирање / пројекти:
- Ретке болести: молекуларна патофизиологија, дијагностички и терапијски модалитети и социјални, етички и правни аспекти (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
- European Commission [FP6-31968, FP7-200754]
DOI: 10.2174/138920011795495277
ISSN: 1389-2002
PubMed: 21453274
WoS: 000291637600004
Scopus: 2-s2.0-79955694748
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Stojiljković, Maja AU - Patrinos, George P. AU - Pavlović, Sonja PY - 2011 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/542 AB - The Human Genome and the Hap Map Projects as well as the extensive use of deep resequencing worldwide, have contributed to a massive catalogue of reported single nucleotide polymorphisms (SNPs) and other genetic variations in the human genome. Pharmacogenomics is an emerging field that combines genetics with pharmacokinetics and pharmacodynamics of the drug in attempt to understand inter-individual differences among patients and develop more accurate drug dosing. However, only for the minority of those variations an association with phenotype has been established. Here, we provide an overview of genes and genetic variants that influence inter-individual dosing of three of the most widely used drugs, namely warfarin, irinotecan and thiopurine drugs, to highlight a tangible benefit of translating genomic knowledge into clinical practice. Therefore, particular SNPs in vitamin K epoxide reductase complex subunit 1 (VKORC1), cytochrome P450 2C9 (CYP2C9), uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1) and thiopurine S-methyltransferase (TPMT) genes has proven to be applicable for optimising the dosage in pursuit of maximum efficacy and minimum adverse effects. Thus, they set an important paradigm of implementation of pharmacogenomics in the mainstream clinical practice. PB - Bentham Science Publ Ltd, Sharjah T2 - Current Drug Metabolism T1 - Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism EP - 454 IS - 5 SP - 445 VL - 12 DO - 10.2174/138920011795495277 ER -
@article{ author = "Stojiljković, Maja and Patrinos, George P. and Pavlović, Sonja", year = "2011", abstract = "The Human Genome and the Hap Map Projects as well as the extensive use of deep resequencing worldwide, have contributed to a massive catalogue of reported single nucleotide polymorphisms (SNPs) and other genetic variations in the human genome. Pharmacogenomics is an emerging field that combines genetics with pharmacokinetics and pharmacodynamics of the drug in attempt to understand inter-individual differences among patients and develop more accurate drug dosing. However, only for the minority of those variations an association with phenotype has been established. Here, we provide an overview of genes and genetic variants that influence inter-individual dosing of three of the most widely used drugs, namely warfarin, irinotecan and thiopurine drugs, to highlight a tangible benefit of translating genomic knowledge into clinical practice. Therefore, particular SNPs in vitamin K epoxide reductase complex subunit 1 (VKORC1), cytochrome P450 2C9 (CYP2C9), uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1) and thiopurine S-methyltransferase (TPMT) genes has proven to be applicable for optimising the dosage in pursuit of maximum efficacy and minimum adverse effects. Thus, they set an important paradigm of implementation of pharmacogenomics in the mainstream clinical practice.", publisher = "Bentham Science Publ Ltd, Sharjah", journal = "Current Drug Metabolism", title = "Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism", pages = "454-445", number = "5", volume = "12", doi = "10.2174/138920011795495277" }
Stojiljković, M., Patrinos, G. P.,& Pavlović, S.. (2011). Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism. in Current Drug Metabolism Bentham Science Publ Ltd, Sharjah., 12(5), 445-454. https://doi.org/10.2174/138920011795495277
Stojiljković M, Patrinos GP, Pavlović S. Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism. in Current Drug Metabolism. 2011;12(5):445-454. doi:10.2174/138920011795495277 .
Stojiljković, Maja, Patrinos, George P., Pavlović, Sonja, "Clinical Applicability of Sequence Variations in Genes Related to Drug Metabolism" in Current Drug Metabolism, 12, no. 5 (2011):445-454, https://doi.org/10.2174/138920011795495277 . .